Press Releases Exelixis, Inc.

Equities

EXEL

US30161Q1040

Delayed Nasdaq Other stock markets 03:57:53 2024-05-21 pm EDT			5-day change	1st Jan Change
20.96 ^USD	-0.45%		-0.12%	-12.61%

May. 20	Exelixis Settles Cabometyx Patent Litigation with Cipla	MT
May. 14	Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA	May. 20	BU
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May	May. 07	BU
Exelixis: Q1 Earnings Snapshot	Apr. 30	AQ
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update	Apr. 30	BU
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024	Apr. 16	BU
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March	Feb. 27	BU
BioInvent International AB Year-end report January 1, December 31, 2023	Feb. 23	AQ
BioInvent International AB Year-end report January 1 – December 31, 2023	Feb. 22	AQ
Exelixis: Q4 Earnings Snapshot	Feb. 06	AQ
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update	Feb. 06	BU
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February	Feb. 01	BU
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024	Jan. 25	BU
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024	Jan. 23	BU
Bristol Myers Squibb - Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits after Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma	Jan. 23	AQ
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX Tablets	Jan. 19	AQ
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets	Jan. 18	BU
BioInvent regains rights to immuno-oncology targets from Exelixis	Jan. 15	AQ
BioInvent regains rights to immuno-oncology targets from Exelixis	Jan. 12	AQ
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024	Jan. 07	BU
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024	Jan. 02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Exelixis, Inc.

Equities

EXEL

US30161Q1040

Press Releases

Filters